What is the recommended duration of treatment with Wellbutrin SR (bupropion) for patients with depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Treatment with Wellbutrin SR (Bupropion) for Depression

For patients with depression, Wellbutrin SR (bupropion) should be continued for at least 4-9 months after achieving remission for a first episode of depression, and for 2 years or longer for patients with recurrent depression (2+ episodes).

Treatment Duration Based on Depression History

The recommended duration of treatment with Wellbutrin SR depends on the patient's depression history:

First Episode of Depression

  • Continue treatment for 4-9 months after achieving remission 1
  • This maintenance period is crucial as discontinuation too early increases relapse risk

Recurrent Depression (2+ episodes)

  • Continue treatment for at least 2 years 1
  • Longer treatment duration is necessary to prevent relapse in patients with multiple episodes

Evidence for Continued Treatment

A placebo-controlled, randomized withdrawal trial demonstrated the efficacy of bupropion SR in the maintenance treatment of major depressive disorder 2:

  • Patients who responded to an 8-week open-label trial of bupropion 300 mg/day were randomized to either continue bupropion or switch to placebo
  • Those who continued bupropion experienced significantly lower relapse rates over the subsequent 44 weeks compared to those switched to placebo 2
  • This study provides strong evidence that maintaining treatment beyond the acute phase significantly reduces relapse risk

Monitoring During Treatment

Regular monitoring is essential during treatment with Wellbutrin SR:

  • Initial assessment within 1-2 weeks of starting therapy 1
  • Comprehensive assessment at 4 weeks to review medication adherence and consider dose adjustments 1
  • After stabilization, follow-up every 3 months to assess continued benefit and monitor for adverse effects 1

Signs of Therapeutic Response

Treatment success should be evaluated based on:

  • Reduction in depressive symptoms using standardized assessment tools
  • Improvements in function and quality of life
  • Absence of significant side effects

Discontinuation Considerations

When discontinuing Wellbutrin SR after the recommended maintenance period:

  • Maintain close follow-up for at least 2-3 months due to high risk of relapse during this period 1
  • The greatest risk of relapse occurs in the first 8-12 weeks after discontinuing medication 1
  • Consider gradual tapering rather than abrupt discontinuation

Risk Factors for Longer Treatment

Patients with the following factors may benefit from extended treatment durations:

  • Multiple previous episodes of depression
  • Severe depressive symptoms
  • Comorbid medical or psychiatric conditions
  • Residual symptoms after acute treatment 1

Special Considerations

Bupropion SR is generally well tolerated with some advantages over other antidepressants:

  • Less likely to cause sexual dysfunction compared to SSRIs 3
  • May be beneficial for patients with depression and comorbid medical conditions 4
  • Can be considered for patients who need assistance with both depression and smoking cessation 3, 5

Remember that premature discontinuation of antidepressant therapy is associated with increased risk of relapse. The decision to discontinue should always be made after careful consideration of the patient's clinical status and risk factors for recurrence.

References

Guideline

Management of Depression with Antidepressants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders.

Primary care companion to the Journal of clinical psychiatry, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.